Language Barriers Linked to Cancer Treatment Delays
-
By
-
Andrea Surnit
-
June 12, 2026
-
4 min
By
Andrea Surnit
June 12, 2026
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.
September 1, 2026